Clinical Trial

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-28; most recent amendment 2026-01-13.
Status change: Active, Not Recruiting → Completed 2026-01-13
Status change: Recruiting → Active, Not Recruiting 2026-01-08
Status change: Not Yet Recruiting → Recruiting 2025-10-15
Trial Details
NCT Number NCT07158398
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Healthy Participants
Enrollment 20 participants
Start Date 2025-10-31
Primary Completion 2025-12-08 (estimated)
Study Completion 2025-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-15